Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands
- PMID: 18661519
- PMCID: PMC2778289
- DOI: 10.1002/ijc.23717
Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands
Abstract
Quantitation of circulating tumor cells (CTCs) can provide information on the stage of a malignancy, onset of disease progression and response to therapy. In an effort to more accurately quantitate CTCs, we have synthesized fluorescent conjugates of 2 high-affinity tumor-specific ligands (folate-AlexaFluor 488 and DUPA-FITC) that bind tumor cells >20-fold more efficiently than fluorescent antibodies. Here we determine whether these tumor-specific dyes can be exploited for quantitation of CTCs in peripheral blood samples from cancer patients. A CTC-enriched fraction was isolated from the peripheral blood of ovarian and prostate cancer patients by an optimized density gradient centrifugation protocol and labeled with the aforementioned fluorescent ligands. CTCs were then quantitated by flow cytometry. CTCs were detected in 18 of 20 ovarian cancer patients (mean 222 CTCs/ml; median 15 CTCs/ml; maximum 3,118 CTCs/ml), whereas CTC numbers in 16 gender-matched normal volunteers were negligible (mean 0.4 CTCs/ml; median 0.3 CTCs/ml; maximum 1.5 CTCs/ml; p < 0.001, chi(2)). CTCs were also detected in 10 of 13 prostate cancer patients (mean 26 CTCs/ml, median 14 CTCs/ml, maximum 94 CTCs/ml) but not in 18 gender-matched healthy donors (mean 0.8 CTCs/ml, median 1, maximum 3 CTC/ml; p < 0.0026, chi(2)). Tumor-specific fluorescent antibodies were much less efficient in quantitating CTCs because of their lower CTC labeling efficiency. Use of tumor-specific fluorescent ligands to label CTCs in peripheral blood can provide a simple, accurate and sensitive method for determining the number of cancer cells circulating in the bloodstream.
Figures


Similar articles
-
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry.Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11760-5. doi: 10.1073/pnas.0703875104. Epub 2007 Jun 29. Proc Natl Acad Sci U S A. 2007. PMID: 17601776 Free PMC article.
-
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.Gynecol Oncol. 2013 Nov;131(2):352-6. doi: 10.1016/j.ygyno.2013.08.006. Epub 2013 Aug 13. Gynecol Oncol. 2013. PMID: 23954902 Clinical Trial.
-
Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.Mol Oncol. 2016 Aug;10(7):1030-42. doi: 10.1016/j.molonc.2016.04.002. Epub 2016 Apr 20. Mol Oncol. 2016. PMID: 27157930 Free PMC article.
-
[Detection of circulating tumor cells from peripheral blood in prostate cancer].Urologe A. 2014 Apr;53(4):509-13. doi: 10.1007/s00120-014-3444-1. Urologe A. 2014. PMID: 24671249 Review. German.
-
[Circulating tumor cells (CTCs)--clinical significance in patients with ovarian cancer].Ginekol Pol. 2012 Apr;83(4):291-4. Ginekol Pol. 2012. PMID: 22712262 Review. Polish.
Cited by
-
Isolation and characterization of circulating tumor cells in prostate cancer.Front Oncol. 2012 Oct 11;2:131. doi: 10.3389/fonc.2012.00131. eCollection 2012. Front Oncol. 2012. PMID: 23087897 Free PMC article.
-
Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancreatic cancer.Cell Prolif. 2020 Sep;53(9):e12880. doi: 10.1111/cpr.12880. Epub 2020 Jul 24. Cell Prolif. 2020. PMID: 32707596 Free PMC article.
-
The combination of folate receptor-positive circulating tumor cells and serum tumor markers suggests a histological diagnosis of lung cancer.J Thorac Dis. 2022 Jan;14(1):158-168. doi: 10.21037/jtd-21-1975. J Thorac Dis. 2022. PMID: 35242377 Free PMC article.
-
The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer.Front Oncol. 2018 Aug 14;8:311. doi: 10.3389/fonc.2018.00311. eCollection 2018. Front Oncol. 2018. PMID: 30155443 Free PMC article. Review.
-
Harnessing the power of Microscale AcoustoFluidics: A perspective based on BAW cancer diagnostics.Biomicrofluidics. 2024 Feb 29;18(1):011304. doi: 10.1063/5.0180158. eCollection 2024 Jan. Biomicrofluidics. 2024. PMID: 38434238 Free PMC article.
References
-
- Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975;35:512–6. - PubMed
-
- Donelli MG, Rosso R, Garattini S. Quantitative studies on cancer dissemination. Cancer Res. 1969;29:414–18. - PubMed
-
- Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34:997–1004. - PubMed
-
- Koike A. Mechanism of blood-borne metastases. I. Some factors affecting lodgment and growth of tumor cells in the lungs. Cancer. 1964;17:450–60. - PubMed
-
- Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical